This approach relies on infusion of G-CSF mobilized peripheral blood mononucleates in patients following standard induction and consolidation chemotherapy for acute myeloid leukemia, however, with no immunosuppressive treatment. This evidence concerns the gene CSF3 and acute myeloid leukemia.